HIV-1-associated nephropathy and response to highly-active antiretroviral therapy

Lancet

Volumn 352, Issue 9130, 1998, Pages 783-784

  Wali, Ravinder K ^a   Drachenberg, Cinthia I ^a   Papadimitnou, John C ^a   Keay, Susan ^a   Ramos, Emilio ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NELFINAVIR; STAVUDINE;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; MALE; PRIORITY JOURNAL;

EID: 0032486998     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)24037-2     Document Type: Article

References (5)

1. Humphreys M H . Human immunodeficency virus-associated glomerulosclerosis. Kidney Int 1995; 48: 311-20.
2. Pastan S, Bailey J. Dialysis therapy. N Eng J Med 1998; 338: 1428-37.
3. Kekow J, Wachsman KW, McCutchan A, et al. Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sei USA 1990;87: 8321-25.
4. Kimmel PL, Bosch JP, Vassalotti JA. Treatment of human immunodeficiency virus-associated nephropathy. Semin Nephrol 1998; 18:446-58.
5. Ifudu O, Rao TKS, Tan CC, et al. Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am J Nephrol 1995; 15: 217-21.